Differential Diagnosis and Interpretation - Complex Clinical Case

Overall Clinical Picture

• Pulmonary fibrosis on imaging (HRCT pattern unspecified)
• High-titre anti-Ro60 antibodies
• Normal Schirmer test, sialometry, parotid ultrasound (no sicca features)
• Normal ESR, CRP, RF, serum proteins, IgG, IgA, IgE
• Low IgM (isolated)
• Low alkaline phosphatase (persistent)
• Low phosphorus, normal PTH, slightly elevated ionized calcium
• Normal spirometry (preserved lung function despite fibrosis - early or restricted not yet detectable)

Part 1: Differential Diagnosis for Pulmonary Fibrosis with Anti-Ro60

1. Interstitial Pneumonia with Autoimmune Features (IPAF) - Most Likely

• Serologic domain: High-titre anti-Ro (SS-A / Ro60) - Murray & Nadel's, Table 92.7
• Morphologic domain: Pulmonary fibrosis present

2. Primary Sjogren's Syndrome with ILD

• Up to 20-30% of Sjogren's patients have subclinical gland involvement early in the disease
• The 2016 ACR/EULAR criteria for pSS require either a lip biopsy (focus score) or anti-Ro/SSA antibody plus another criterion; with zero sicca symptoms or signs, the diagnosis does not hold
• ILD in Sjogren's typically presents as NSIP or LIP (lymphocytic interstitial pneumonia)
• Sjogren's ILD is associated with both anti-Ro52 and anti-Ro60 - this distinction matters (see below)

3. Subclinical/Incomplete SLE

4. Idiopathic Pulmonary Fibrosis (IPF) with Incidental Anti-Ro60

5. Hypersensitivity Pneumonitis (HP) - Chronic Fibrotic Form

6. Anti-synthetase Syndrome / Antisynthetase Without Myositis

Critical Note on Anti-Ro52 vs. Anti-Ro60 and ILD

Part 2: Low IgM - What Does It Mean?

Selective IgM Deficiency (sIgMD)

• ~80% of symptomatic patients have recurrent bacterial, viral, or fungal infections. Encapsulated bacteria (S. pneumoniae, H. influenzae) are especially dangerous since IgM is the primary opsonizing antibody in early responses.
• ~1/3 of sIgMD patients develop autoimmune diseases - SLE, rheumatoid arthritis, autoimmune thrombocytopenia, Hashimoto's thyroiditis, Addison's disease - as shown in Immune Deficiency Foundation data and Frontiers in Immunology (2017).
• The mechanism linking low IgM to autoimmunity: IgM normally promotes clearance of apoptotic cells and self-antigens; deficiency impairs this clearance, allowing self-antigen accumulation and triggering autoantibody production. This is a plausible mechanism for the anti-Ro60 antibodies in this patient.
• In this patient, the combination of sIgMD + anti-Ro60 antibodies fits the pattern of sIgMD-associated autoimmunity.
• Secondary causes of low IgM (medications, myeloma, lymphoma) should be excluded before labeling primary sIgMD.

Part 3: Low Alkaline Phosphatase - What Does It Mean?

Primary Consideration: Hypophosphatasia (HPP) - Mild Adult Form

• Low ALP
• Low phosphorus (ALP normally promotes inorganic phosphate liberation)
• Slightly elevated ionized calcium (reduced bone mineralization releases calcium)
• Normal PTH (excludes hypoparathyroidism as the cause)

• Chondrocalcinosis and calcific periarthropathy
• Stress fractures and osteomalacia
• Dental problems (premature tooth loss)
• Occasionally, bone/muscle pain

Other Causes of Low ALP to Consider

Summary and Recommended Next Steps

The Three Independent Problems in This Patient

Treatment Plan - Addressing Each Problem in This Patient

Problem 1: Pulmonary Fibrosis / IPAF

Step 1 - The HRCT Pattern is the Treatment Decision Fork

• Treat as CTD-ILD / IPAF-NSIP with immunosuppression
• Expected better response and prognosis than UIP

• Treat as IPAF-UIP (behaviorally close to IPF)
• Avoid aggressive immunosuppression; lean toward antifibrotics
• PMC 2024 review confirms immunosuppression is often avoided in IPAF-UIP due to the PANTHER-IPF lesson (azathioprine + prednisone + NAC increased mortality in UIP/IPF)

For IPAF-NSIP (non-UIP pattern):

1. Mycophenolate mofetil (MMF) - 500 mg twice daily, titrating to 1000-1500 mg twice daily as tolerated. This is the current preferred steroid-sparing agent for CTD-ILD/IPAF. Better tolerated than azathioprine in diabetic elderly patients.
2. Hydroxychloroquine (200-400 mg/day, adjusted for lean body weight, max 5 mg/kg/day to avoid retinopathy) - particularly useful given the anti-Ro antibody profile and as a low-toxicity baseline drug. Commonly used in Sjogren's-associated ILD and IPAF with SSA positivity.
3. Corticosteroids - used cautiously. Low-dose prednisone (10-20 mg/day) as a bridge while MMF takes effect (3-6 months), then taper to the lowest effective dose or off. Critical caveat: this patient is diabetic - corticosteroids will worsen glycaemic control and must be used at the lowest possible dose with close glucose monitoring. Metformin may need to be complemented with or replaced by insulin during steroid courses.
4. Azathioprine is an alternative to MMF (1-2 mg/kg/day) but requires TPMT testing before use; generally second choice in elderly diabetics.

For IPAF-UIP (UIP pattern):

1. Nintedanib 150 mg orally twice daily - the INBUILD trial showed it reduces FVC decline in progressive fibrosing ILD beyond IPF, including IPAF. It is now approved for progressive fibrosing ILD regardless of ILD type. Main side effects: diarrhea (very common), nausea, hepatotoxicity - LFTs must be monitored. Important interaction: nintedanib is a substrate of P-gp and CYP3A4; use with caution if the patient is on any medications using these pathways.
2. Pirfenidone (up to 2403 mg/day in three divided doses) as an alternative - both agents slow FVC decline comparably in IPF per Goldman-Cecil Medicine 22e. Retrospective data show pirfenidone also stabilizes FVC in IPAF at 3, 12, and 24 months per PMC 2024. Side effects: photosensitivity, GI upset, fatigue.
3. Some experts use low-dose immunosuppression + antifibrotic together for IPAF-UIP if strong serological features are present (high-titre anti-Ro60 in this case). The INBUILD trial showed baseline immunosuppression did not worsen outcomes.

Monitoring without DLCO:

• Serial FVC spirometry every 3-6 months - a decline of >10% absolute or >5% with worsening symptoms is the standard definition of progression
• 6-minute walk test - a practical surrogate for functional impairment
• Serial HRCT (annually or if clinically deteriorating) to assess fibrosis extent
• Resting oxygen saturation and assessment during exertion
• If desaturation on exertion: supplemental oxygen prescription

Universal ILD Supportive Measures:

• Pulmonary rehabilitation - exercise training improves exercise capacity and quality of life in all ILD patients regardless of cause
• Vaccinations - pneumococcal (PPSV23 + PCV15/20), annual influenza, COVID-19, herpes zoster - especially important given his sIgMD (see below)
• Proton pump inhibitors - treat gastroesophageal reflux aggressively (silent microaspiration contributes to ILD progression)
• Avoid smoking and occupational exposures
• Lung transplant - he is 68 years old; this is a relative contraindication (most centers use 70 as the upper limit). Still worth a transplant center referral if disease progresses, particularly if he has good functional status

Problem 2: Selective IgM Deficiency (sIgMD)

1. Vaccine-specific antibody testing - check pneumococcal-specific IgG antibody titers before and 4 weeks after pneumococcal vaccination. If he has an impaired response (< 4-fold rise or < protective threshold), he may qualify for IgG replacement therapy (subcutaneous or intravenous immunoglobulin - SCIG or IVIG). Per Frontiers in Immunology and MDPI Diagnostics 2023: IVIG/SCIG may be beneficial in sIgMD patients with recurrent infections AND impaired specific antibody responses.
2. Vaccinations - pneumococcal (both conjugate and polysaccharide), influenza, COVID, herpes zoster (use recombinant Shingrix - not live vaccine given immunodeficiency status).
3. Prompt antibiotic treatment of infections - do not defer. Encapsulated bacteria (S. pneumoniae, H. influenzae) are the main threat.
4. No prophylactic antibiotics routinely recommended unless recurrent proven bacterial infections occur.
5. The autoimmune manifestations (anti-Ro60, ILD) are treated as described above - the underlying sIgMD is a permissive backdrop, not separately treatable for the autoimmune component.

Problem 3: Probable Hypophosphatasia (HPP) - Adult Form

Confirm the Diagnosis First:

• Measure serum pyridoxal-5'-phosphate (PLP / vitamin B6) - if elevated, this is highly sensitive and specific for HPP (Firestein & Kelley's Rheumatology)
• Measure urinary phosphoethanolamine (elevated in HPP, though less specific)
• ALPL gene sequencing - confirms the diagnosis
• Meanwhile, exclude secondary causes: TSH (hypothyroidism lowers ALP), review all medications (glucocorticoids, fibrates, bisphosphonates all lower ALP), nutritional assessment (zinc, magnesium, B12 deficiency)

Treatment of Adult HPP:

1. Asfotase alfa (bone-targeted recombinant TNSALP, 1 mg/kg subcutaneously three times weekly or 2 mg/kg twice weekly) - FDA-approved for HPP. PMC 2024 data show adults receiving asfotase alfa for 6+ months had improvements in mobility, physical function, and quality of life. Indications in adults typically include history of childhood-onset HPP, or significant complications (fractures, chondrocalcinosis, severe osteomalacia). For a mild asymptomatic adult form, the benefit-cost ratio is debated.
2. Physical and occupational therapy - fracture prevention, fall prevention, muscle strengthening. This is often the main intervention in mild adult forms per Firestein & Kelley's.
3. Calcium and phosphate supplementation - avoid aggressive supplementation as this can worsen pyrophosphate accumulation and calcific arthropathy.
4. CRITICAL WARNING - Bisphosphonates are CONTRAINDICATED in HPP. This is a life-safety issue. Since this patient is a 68-year-old diabetic with low bone density risk, a well-meaning clinician might prescribe alendronate or zoledronic acid "for bone protection." This must not happen - bisphosphonates worsen osteomalacia in HPP and are associated with atypical femoral fractures in HPP adults. The consensus is clear: bisphosphonates should not be used in HPP.
5. Denosumab - also use with great caution; it is not a bisphosphonate but acts on osteoclasts and its safety in HPP is not established.
6. Optimize vitamin D status (25-OH-D target 30-50 ng/mL) and ensure adequate protein/zinc/magnesium intake, as deficiencies further impair the residual ALP activity.

Problem 4: Diabetes Management - Important Drug Interactions

• Corticosteroids (if used for ILD) will raise blood glucose significantly. Pre-emptive adjustment of antidiabetic therapy is needed; coordinate with endocrinology.
• Nintedanib and pirfenidone have no major direct interactions with common diabetic agents, but liver function monitoring is important as hepatic dysfunction affects metformin safety.
• Metformin should be withheld if renal function deteriorates (eGFR < 30) or during contrast procedures.
• Low phosphorus may compound bone fragility already increased by diabetic osteopathy.

Summary Treatment Priorities

Question 1: Is Hydroxychloroquine Recommended in ILD with UIP Pattern?

What the evidence says about HCQ in UIP:

• Modulation of toll-like receptor signalling (inhibits TLR7/9)
• Reduction of autoantibody production
• Anti-inflammatory via lysosomal pH disruption
• Antithrombotic effects

• IPF guidelines (ATS/ERS): HCQ is not recommended; it does not appear in IPF treatment algorithms
• IPAF-UIP: Treatment leans toward antifibrotics (nintedanib per INBUILD), not immunosuppressants or antimalarials
• RA-ILD with UIP: The 2023 ACR/CHEST guidelines do not include HCQ in the ILD treatment algorithm (it is used for RA joint disease, not for the ILD component)

When HCQ might still be used in this patient:

• In a patient with anti-Ro60 antibodies and suspected IPAF/CTD overlap, HCQ may reduce the autoimmune drive that could be contributing to ongoing lung injury
• In Sjogren's-associated ILD (NSIP pattern), some case series included HCQ as part of combination regimens alongside steroids and azathioprine, with improvement in 3/5 patients (ERS Review on pulmonary Sjogren's)
• As a low-toxicity add-on for systemic autoimmune disease control (arthralgia, skin, serologic activity) without worsening the fibrosis

Question 2: What If There Is No Access to HRCT?

What plain chest X-ray (CXR) can and cannot tell you:

• CXR can detect ILD but has variable sensitivity - it misses early disease regularly
• It cannot reliably distinguish UIP from NSIP pattern
• However: in a patient where ILD is already known to be present (as in your case - fibrosis was "discovered"), CXR can still provide useful staging information

CXR features that suggest UIP vs. NSIP (imperfect but practical):

The probabilistic approach without HRCT:

• Clinical profile (age, sex, diabetes, anti-Ro60, serology)
• CXR pattern
• Spirometry (already done - normal)
• Clinical course (progressive vs. stable)

• Age 68 with anti-Ro60 in high titre
• No heavy smoking history mentioned
• Normal spirometry (early disease, could be either)
• Autoimmune serology and IPAF profile
• NSIP is more common in IPAF/CTD (65% of IPAF cases) - Fishman's Pulmonary

• Age 68, male, diabetic (all risk factors for IPF)
• Normal Schirmer/sialometry/parotid (arguing against active Sjogren's)
• Anti-Ro60 specifically less linked to ILD than anti-Ro52

Practical treatment decision without HRCT:

• Hydroxychloroquine 200-400 mg/day (low toxicity, useful for the autoimmune component regardless of pattern, will not harm a UIP patient directly)
• Low-dose prednisone (10-15 mg/day) for 2-3 months as a diagnostic-therapeutic trial, with very careful glucose monitoring (this patient is diabetic)
• If FVC improves or stabilises at 3-6 months: consistent with inflammatory/NSIP-type disease - continue and add MMF
• If FVC declines despite steroids: consistent with UIP/fibrotic disease - stop immunosuppression, add antifibrotic

• Switch to antifibrotic (nintedanib or pirfenidone) - both are licensed for progressive fibrosing ILD beyond confirmed IPF/UIP; the INBUILD trial included patients based on progressive phenotype (>5% FVC decline over 24 months), not HRCT pattern
• FVC decline >5% absolute in 12 months is your trigger for switching to antifibrotic strategy

• Serial FVC every 3-6 months
• 6-minute walk test
• Clinical assessment of symptoms, exertional desaturation (pulse oximetry)

Additional Practical Notes for Limited-Resource Setting:

• Bronchoalveolar lavage (BAL) via bronchoscopy, if available, can provide pattern information: lymphocytosis suggests NSIP/HP/CTD-ILD; neutrophilia suggests UIP/IPF. Not definitive but helpful.
• KL-6 serum biomarker - elevated in active ILD (type II pneumocyte marker); useful for monitoring activity in settings where repeated imaging is limited. Correlates with ILD severity.
• Surgical lung biopsy - if truly undecided and the patient's condition warrants it, this is the definitive answer. Unlikely to be feasible in a limited-resource setting.
• Transbronchial cryobiopsy - a less invasive alternative to surgical biopsy for ILD pattern diagnosis; if bronchoscopy is available, this may give a histological pattern (UIP vs. NSIP) that guides therapy definitively.

Summary for This Patient Without HRCT or DLCO

1. Start HCQ (200-400 mg/day) as background autoimmune control - low risk, no diabetes interaction
2. Short steroid trial (prednisone 10-15 mg/day x 8-12 weeks) with glucose monitoring - diagnostic and therapeutic
3. Monitor FVC every 3 months as your primary endpoint
4. If responds (FVC stable/improving): add MMF, taper steroids, continue HCQ
5. If does not respond or FVC falls >5%: add or switch to nintedanib/pirfenidone, reduce/stop steroids
6. Do not give bisphosphonates for any "osteoporosis" found incidentally - HPP is present
7. Vaccinate aggressively given sIgMD